Halozyme Therapeutics, Inc.
HALO · Nasdaq
HALO · Nasdaq
Halozyme Therapeutics is a biotechnology company whose publicly described investment case centers on drug-delivery technology and royalty growth. The supplied evidence does not provide a complete segment breakdown, named products, customer list, or contribution by business line. It does indicate that royalties are an important source of growth and that the company generated $1.4 billion of FY2025 revenue and $0.3 billion of net income, compared with $1.0 billion and $0.4 billion, respectively, in FY2024. Its scale is therefore established by billion-dollar annual revenue, although the evidence does not quantify employees, products, partners, or geographic reach.
